Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

Viking Therapeutics faces tough obesity drug rivals, with VK2735 showing promise but an uncertain edge. Find out why VKTX ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, ...

We recently published a list of Did Jim Cramer Nail or Miss These 11 Stock Predictions? In this article, we are going to take ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

Novo Nordisk is making a strategic push into India's weight-loss market to secure its position ahead of competition from ...

Nevertheless, European companies have found themselves in the sights of America’s president, who is irked by the fact that ...

Telemonitoring with continuous glucose monitoring and insulin pens outperforms standard-of-care practices for improving ...

HIMS posted stellar Q1 FY 2025; growth fueled by ~2.4M subscribers and $84 average monthly revenue per user. Click here to ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...